Cytek BioSciences（CTKB）在专利诉讼中赢得重要胜利。陪审团对其四项专利主张中的三项作出了有利裁决，这家生物科学公司表示将继续就剩余的一项裁决发起挑战。
这一消息无疑为Cytek BioSciences的投资者注入了一剂强心针。陪审团的裁决结果意味着，在四起核心专利纠纷中，该公司已在其中三起案件中占据了上风。
尽管如此，Cytek BioSciences并未满足于当前战果。公司明确表态，将对剩余一项尚未获得支持的裁决结果提出异议，展现出捍卫自身知识产权权益的坚定决心。
这场专利之争的阶段性胜利，不仅巩固了Cytek BioSciences在行业内的技术地位，也可能为其未来的市场竞争格局带来积极影响。随着公司计划进一步挑战剩余的裁决结果，这场法律拉锯战的最终走向仍值得市场持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.